Nymox Pharmaceutical Co. (NASDAQ:NYMX – Get Rating) Director James George Robinson purchased 1,151,515 shares of the stock in a transaction that occurred on Monday, May 2nd. The shares were bought at an average cost of $1.65 per share, for a total transaction of $1,899,999.75. Following the acquisition, the director now owns 4,702,065 shares of the company’s stock, valued at $7,758,407.25. The transaction was disclosed in a filing with the SEC, which is available through this link.
Shares of NYMX opened at $1.33 on Friday. Nymox Pharmaceutical Co. has a 1 year low of $0.94 and a 1 year high of $2.27. The company’s fifty day moving average is $1.45 and its two-hundred day moving average is $1.47.
Several large investors have recently modified their holdings of the company. Millennium Management LLC increased its stake in shares of Nymox Pharmaceutical by 1,834.9% during the second quarter. Millennium Management LLC now owns 323,364 shares of the biopharmaceutical company’s stock worth $511,000 after acquiring an additional 306,652 shares during the period. Morgan Stanley raised its stake in shares of Nymox Pharmaceutical by 15.9% during the 2nd quarter. Morgan Stanley now owns 76,239 shares of the biopharmaceutical company’s stock worth $120,000 after buying an additional 10,471 shares in the last quarter. Geode Capital Management LLC lifted its holdings in shares of Nymox Pharmaceutical by 21.8% in the 3rd quarter. Geode Capital Management LLC now owns 50,731 shares of the biopharmaceutical company’s stock valued at $104,000 after buying an additional 9,086 shares during the period. Goldman Sachs Group Inc. boosted its stake in shares of Nymox Pharmaceutical by 71.0% in the second quarter. Goldman Sachs Group Inc. now owns 48,736 shares of the biopharmaceutical company’s stock valued at $77,000 after buying an additional 20,236 shares in the last quarter. Finally, Advisor Group Holdings Inc. grew its holdings in Nymox Pharmaceutical by 365.4% during the third quarter. Advisor Group Holdings Inc. now owns 12,100 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 9,500 shares during the period. 1.09% of the stock is currently owned by institutional investors and hedge funds.
About Nymox Pharmaceutical (Get Rating)
Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population in Canada, the United States, Europe, and internationally. Its lead drug candidate is Fexapotide Triflutate (NX-1207), which has completed Phase III clinical trials for the treatment of benign prostatic hyperplasia, and Phase II clinical trials for low grade localized prostate cancer, as well as is in preclinical studies for hepatocellular carcinoma.
- Get a free copy of the StockNews.com research report on Nymox Pharmaceutical (NYMX)
- Expedia or Bookings Holdings: Which Stock Should You Travel With?
- Is This The Bottom For Papa John’s International?
- Kellogg Company Flexes Pricing Power, Shares Move Higher
- Peak Growth Is Over For Etsy
- Uber Fails To Impress
Receive News & Ratings for Nymox Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nymox Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.